5535 studies found for:    "Breast Neoplasms"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
2 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
3 Active, not recruiting Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel;   Drug: Paclitaxel
4 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
5 Active, not recruiting Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors
Conditions: Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Other: questionnaire administration;   Behavioral: exercise intervention;   Procedure: quality-of-life assessment;   Other: survey administration;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
6 Active, not recruiting Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer - BRCA1;   Hereditary Breast/Ovarian Cancer - BRCA2;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: cisplatin;   Drug: vinorelbine tartrate;   Other: laboratory biomarker analysis;   Other: pharmacological study
7 Active, not recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
8 Active, not recruiting Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of Breast;   Cancer of the Breast;   Human Mammary Carcinoma;   Neoplasms, Breast
Interventions: Procedure: Remove tumor only;   Procedure: Removal of tumor and tissue
9 Terminated RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: exemestane;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: goserelin acetate
10 Not yet recruiting Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Lobular Breast Carcinoma in Situ;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: accelerated partial breast irradiation;   Radiation: intensity-modulated radiation therapy;   Radiation: image-guided radiation therapy;   Procedure: therapeutic conventional surgery;   Other: questionnaire administration;   Other: laboratory biomarker analysis
11 Completed 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Conditions: Advanced Adult Primary Liver Cancer;   Carcinoma of the Appendix;   Estrogen Receptor-negative Breast Cancer;   Extensive Stage Small Cell Lung Cancer;   Gastrointestinal Stromal Tumor;   HER2-negative Breast Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor;   Recurrent Breast Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Small Intestine Adenocarcinoma;   Small Intestine Leiomyosarcoma;   Small Intestine Lymphoma;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Anal Cancer;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Gastric Cancer;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer;   Triple-negative Breast Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: 7-hydroxystaurosporine;   Drug: irinotecan hydrochloride;   Other: diagnostic laboratory biomarker analysis
12 Completed Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: tipifarnib;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
13 Completed Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers
Conditions: Breast Cancer;   Ductal Breast Carcinoma in Situ;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Other: educational intervention;   Procedure: quality-of-life assessment;   Other: Questionnaire Administration;   Other: psychosocial support for caregiver;   Procedure: assessment of therapy complications;   Other: informational intervention
14 Recruiting Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
15 Active, not recruiting Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: entinostat;   Drug: azacitidine;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Active, not recruiting MUC1 Vaccine for Triple-negative Breast Cancer
Conditions: Breast Cancer;   Inflammatory Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine;   Biological: poly ICLC;   Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry
17 Active, not recruiting Capecitabine in Women With Operable Breast Cancer
Conditions: Invasive Breast Carcinoma;   Primary Invasive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Intervention: Drug: Capecitabine
18 Recruiting Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of the Breast;   Neoplasms, Breast;   Tumors, Breast
Interventions: Drug: Eribulin;   Drug: Doxorubicin;   Drug: Cyclophosphamide
19 Recruiting Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Conditions: HER2-Negative Breast Cancer;   Triple Negative Breast Cancer;   Breast Cancer;   Cancer of Breast;   Breast Tumors
Interventions: Drug: E7389 (Eribulin Mesylate);   Drug: Vinorelbine injection
20 Recruiting Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: carboplatin;   Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years